The safety profile of RINVOQ was consistent with that observed in previously reported studies, with no new safety risks detected. Through week 24, serious infections occurred in 1.2 percent and 2.6 percent of patients in the 15 mg and 30 mg RINVOQ groups, respectively, compared to 0.9 percent in the placebo group and 0.7 percent in the adalimumab group. There was one case of adjudicated venous thromboembolic events (VTE) in the RINVOQ 30 mg group (0.2 percent), no cases in the RINVOQ 15 mg group, two cases in the adalimumab group (0.5 percent) and one case in the placebo group (0.2 percent).No major adverse cardiovascular events (MACE) were reported in either RINVOQ group. There was one MACE reported in the placebo group and two MACE reported in the adalimumab group. There were no deaths in either RINVOQ group, one death in the placebo group (0.2 percent) and no deaths in the adalimumab group.